Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease. Data from the positive Phase 2 study evaluating rilzabrutinib for the treatment of IgG4-relat ...

Streamex is a RWA and gold tokenization company building Institutional grade infrastructure to bring the gold market on chain, enabled by a gold denominated treasury and an institutional grade ...

Zealand Pharma Announces Financial Results for the First Half of 2025 Petrelintide collaboration with Roche off to a strong start, while key leadership appointments and solid financial position enable ...

Half Year Results 2025 – Webcast Kuros will host a virtual webcast to discuss H1 2025 financial results on August 14, 2025, at 3:00pm CET. Investors can join the webcast via the following link: ...